HARVONI VERSUS 3D REGIMENS OUTCOMES AMONG HCV INFECTED PATIENTS VISITED KURDISTAN CENTER FOR GASTROENTEROLOGY AND HEPATOLOGY (KCGH).

Volume 12 , Issue 1 , March 2022 , Pages 1-9

Authors

Mohammed Omer Lak 1 ; Mohammed Omer Mohammed 2 ; Muhsin A. Mohammed 1 ; Ali Jabbar Ahmad 1

1 Kurdistan Board candidate, Kurdistan Center for Gastroenterology, Kurdistan Region, Iraq.

2 College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.

DOI logo 10.17656/jsmc.10338

Keywords

Abstract

Background
Approximately 3% of the world’s population is infected by the Hepatitis C virus (HCV), and more than
2/3rd of patients have chronic hepatitis. The recent revolutions in HCV treatment have led the World Health
Organization to target its elimination as a public health threat by 2030.
Objectives
To evaluate and compare the efficacy of two therapeutic regimens in HCV management.
Patients and Methods
This is a comparative prospective clinical study was conducted on 88 patients with HCV at Kurdistan Center
for gastroenterology and hepatology (KCGH) in a teaching hospital in the Sulaimaniah City-Kurdistan region
of Iraq from January 2020 to December 2020.
The patients were divided into two groups; one group received Harvoni (sofosbuvir/ledipasvir), and the other
group was given three-drug regimens (Exviera plus Viekrax (ombitasvir/paritaprevir/ritonavir plus dasabuvir)
for 12 weeks. The collected data before and after treatment were analyzed through Statistical Package for the
Social Sciences (SPSS version 26.0).
Results
The patients’ mean age was found to be 38.6 years. Males were accounted for a more significant number
of the patients (55.7%). The two groups were not significantly different in terms of age, gender, nationality,
occupation, BMI, DM, and risk factors (P-value>0.05). But a significant difference was seen between them
in terms of their initial glomerular filtration rate (p-value=0.003). In addition, the patients’ gender, age, and
HCV genotype were not significantly correlated with their sustain virology response (SVR). Also, a significant
difference was observed between the two groups in terms of SVR after three months of treatment, such that
more patients who received Harvoni achieved SVR. Moreover, there was a significant relationship between the
initial fibrosis stage and the patients’ SVR to the treatment (p-value=0.01).
Conclusion
Compared to the 3 D regimens (Exviera plus Viekrax), Harvoni was more effective for treating patients with
chronic HCV.

Statistics
  • Article view494
  • Downloads2
  • Published at21 March 2022

  • RIS
  • BibTeX
  • EndNote
  • Mendeley
  • APA (7th edition)
  • MLA (9th edition)
  • Chicago
  • Harvard
  • IEEE
  • Vancouver